Title: | Clinical Guidelines for Somatostatin Receptor Imaging and Peptide Receptor Radionuclide Therapy of Neuroendocrine Tumor (2022) |
Edition: | Original |
Classification: | Standard guideline |
Field: | Diagnosis and Treatment |
Countries and regions: | China |
Guidelines users: | |
Evidence classification method: | This consensus mainly includes two types of evidence: First, high-level evidence-based medical evidence (Category 1), which is unanimously agreed by the expert group and strongly recommended (A); Second, the level of evidence is slightly lower (Category 2), but the expert group basically agrees, and it is moderately recommended (B). Other levels of evidence will not be currently included. |
Development unit: | Chinese Society of Nuclear Medicine, Chinese Neuroendocrine Tumor Society |
Registration time: | 2022-04-15 |
Registration number: | IPGRP-2022CN229 |
Purpose of the guideline: |
Latest registration